Felix Dietlein

9PUBLICATIONS
36CO-AUTHORS
Molecular targetsReaction engineering (excl. nuclear reactions)Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Apr 03, 2026
Single-cell transcriptomics reveals FXR1 as an actionable target for siRNA therapy in ovarian cancer.

Jasmine George, Xiaolong Ma, Ishaque Pulikkal Kadamberi

|Jan 28, 2026
Airborne Radioiodine: A Comparative View of Chemical Forms in Medicine, Nuclear Industry, and Fallout Scenarios.

Klaus Schomäcker, Ferdinand Sudbrock, Thomas Fischer

|Jul 12, 2025
Overcoming Multidrug Resistance Using DNA-Localized Auger Emitters: A Comparative Analysis of Radiotoxicity in Breast Cancer Cells.

Klaus Schomäcker, Beate Zimmermanns, Thomas Fischer

|Oct 16, 2024
Tumoricidal Activity and Side Effects of Radiolabeled Anti-NCAM [<sup>131</sup>I]-Iodine-ERIC1 in Neuroblastoma-Bearing Mice.

Thomas Fischer, Felix Dietlein, Detlev Bongartz

|Oct 16, 2024
Localization and Tumor Growth Inhibition of I-131-Labeled Monoclonal Antibody ERIC1 in a Subcutaneous Xenograft Model of Small Cell Lung Cancer in SCID Mice.

Thomas Fischer, Christopher Dietrich, Felix Dietlein

|Sep 08, 2022
Mutational Footprint of Platinum Chemotherapy in a Secondary Thyroid Cancer.

Julia Schiantarelli, Theodora Pappa, Jake Conway

Pageof 2